Approaches for monitoring of non virus-specific and virus-specific T-cell response in solid organ transplantation and their clinical applications

Journal of Clinical Virology

Volumn 70, Issue , 2015, Pages 109-119

  Calarota, Sandra A ^a   Aberle, Judith H ^b   Puchhammer Stöckl, Elisabeth ^b   Baldanti, Fausto ^a,c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Human cytomegalovirus; Immune monitoring approaches; Polyoma BK virus; Solid organ transplantation; T cell immunity

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; MITOGENIC AGENT; VIRUS ANTIGEN; ANTIGEN; IMMUNOSUPPRESSIVE AGENT; T LYMPHOCYTE RECEPTOR;

ASSAY; BK VIRUS; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GRAFT RECIPIENT; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE CELL FUNCTION ASSAY; MONITORING; OPPORTUNISTIC VIRAL INFECTION; ORGAN TRANSPLANTATION; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; RISK; SOLID ORGAN TRANSPLANTATION; STAINING; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION; BIOSYNTHESIS; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; OPPORTUNISTIC INFECTIONS; VIROLOGY; VIRUS DISEASES;

ANTIGENS; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TRANSPLANT RECIPIENTS; VIRUS DISEASES;

EID: 84939625843     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.07.299     Document Type: Review

References (135)

1. Fishman J.A., Issa N.C. Infection in organ transplantation: risk factors and evolving patterns of infection. Infect. Dis. Clin. North Am. 2010, 24(2):273-283.
2. Battegay M., Nüesch R., Hirschel B., Kaufmann G.R. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect. Dis. 2006, 6(5):280-287.
3. Zegleń S., Łaszewska A., Wojarski J., Woźniak-Grygiel E., Zakliczyński M., Ochman M., et al. Lymphocyte subtypes CD3+, CD19+, CD16+CD56+, CD4+, CD8+, and CD3+HLA-DR+ in peripheral blood obtained from patients after thoracic organ transplantation. Transplant. Proc. 2011, 43(8):3055-3057.
4. Calarota S.A., Zelini P., De Silvestri A., Chiesa A., Comolli G., Sarchi E., et al. Kinetics of T-lymphocyte subsets and posttransplant opportunistic infections in heart and kidney transplant recipients. Transplantation 2012, 93(1):112-119.
5. Lanio N., Sarmiento E., Gallego A., Navarro J., Palomo J., Fernandez-Yañez J., et al. Kinetics of functionally distinct T-lymphocyte subsets in heart transplant recipients after induction therapy with anti-CD25 monoclonal antibodies. Transpl. Immunol. 2013, 28(4):176-182.
6. Fernández-Ruiz M., López-Medrano F., Allende L.M., Andrés A., García-Reyne A., Lumbreras C., et al. Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation. Transpl. Int. 2014, 27(7):674-685.
7. Elshal M.F., McCoy J.P. Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 2006, 38(4):317-323.
8. Zedtwitz-Liebenstein K., Jaksch P., Wulkersdorfer B., Friehs H., Pempelfort S.D., Burgmann H., et al. Usefulness of interleukin-10 detection in lung transplant patients with human cytomegalovirus infection with respect to virus persistence. Transplantation 2007, 84(2):268-271.
9. Patella M., Anile M., Del Porto P., Diso D., Pecoraro Y., Onorati I., et al. Role of cytokine profile in the differential diagnosis between acute lung rejection and pulmonary infections after lung transplantation. Eur. J. Cardiothorac. Surg. 2015, 47(6):1031-1036.
10. Jackson J.A., Kim E.J., Begley B., Cheeseman J., Harden T., Perez S.D., et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am. J. Transplant. 2011, 11(10):2228-2234.
11. Husain S., Resende M.R., Rajwans N., Zamel R., Pilewski J.M., Crespo M.M., et al. Elevated CXCL10 (IP-10) in bronchoalveolar lavage fluid is associated with acute cellular rejection after human lung transplantation. Transplantation 2014, 97(1):90-97.
12. Rollag H., Ueland T., Asberg A., Hartmann A., Jardine A.G., Humar A., et al. Characterization of cytomegalovirus disease in solid organ transplant recipients by markers of inflammation in plasma. PLoS One 2013, 8(4):e60767.
13. Weseslindtner L., Görzer I., Küng E., Roedl K., Jaksch P., Klepetko W., et al. High CXCL-16 levels correlate with symptomatic disease in lung transplant recipients with human cytomegalovirus replication in the allograft. Am. J. Transplant. 2014, 14(10):2406-2411.
14. Kowalski R., Post D., Schneider M.C., Britz J., Thomas J., Deierhoi M., et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin. Transplant. 2003, 17(2):77-88.
15. Kowalski R.J., Post D.R., Mannon R.B., Sebastian A., Wright H.I., Sigle G., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006, 82(5):663-668.
16. Rodrigo E., López-Hoyos M., Corral M., Fábrega E., Fernández-Fresnedo G., San Segundo D., et al. ImmuKnow as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: a systematic review and meta-analysis. Liver Transpl. 2012, 18(10):1245-1253.
17. Ling X., Xiong J., Liang W., Schroder P.M., Wu L., Ju W., et al. Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis. Transplantation 2012, 93(7):737-743.
18. Huskey J., Gralla J., Wiseman A.C. Single time point immune function assay (ImmuKnow) testing does not aid in the prediction of future opportunistic infections or acute rejection. Clin. J. Am. Soc. Nephrol. 2011, 6(2):423-429.
19. ) results in the first year post-transplant and relationship to BK virus infection. Nephrol. Dial. Transplant. 2012, 27(6):2565-2570.
20. Quaglia M., Cena T., Fenoglio R., Musetti C., Cagna D., Radin E., et al. Immune function assay (immunknow) drop over first 6 months after renal transplant: a predictor of opportunistic viral infections?. Transplant. Proc. 2014, 46(7):2220-2223.
21. Kotton C.N., Kumar D., Caliendo A.M., Asberg A., Chou S., Danziger-Isakov L., et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013, 96(4):333-360.
22. Sageshima J., Ciancio G., Chen L., Dohi T., El-Hinnawi A., Paloyo S., et al. Lack of clinical association and effect of peripheral WBC counts on immune cell function test in kidney transplant recipients with T-cell depleting induction and steroid-sparing maintenance therapy. Transpl. Immunol. 2014, 30(2-3):88-92.
23. Suviolahti E., Petrosyan A., Mirocha J., Ge S., Karasyov A., Thomas D., et al. Significant reduction of ATP production in PHA-activated CD4+ cells in 1-day-old blood from transplant patients. Transplantation 2012, 94(12):1243-1249.
24. Remakus S., Sigal L.J. Memory CD8(+) T cell protection. Adv. Exp. Med. Biol. 2013, 785:77-86.
25. Sant A.J., McMichael A. Revealing the role of CD4(+) T cells in viral immunity. J. Exp. Med. 2012, 209(8):1391-1395.
26. Altman J.D., Moss P.A., Goulder P.J., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996, 274(5284):94-96.
27. Brosterhus H., Brings S., Leyendeckers H., Manz R.A., Miltenyi S., Radbruch A., et al. Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion. Eur. J. Immunol. 1999, 29(12):4053-4059.
28. Waldrop S.L., Pitcher C.J., Peterson D.M., Maino V.C., Picker L.J. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J. Clin. Invest. 1997, 99(7):1739-1750.
29. Czerkinsky C., Andersson G., Ekre H.P., Nilsson L.A., Klareskog L., Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Methods 1988, 110(1):29-36.
30. Czerkinsky C.C., Nilsson L.A., Nygren H., Ouchterlony O., Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods 1983, 65(1-2):109-121.
31. Walker S., Fazou C., Crough T., Holdsworth R., Kiely P., Veale M., et al. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl. Infect. Dis. 2007, 9(2):165-170.
32. Kiecker F., Streitz M., Ay B., Cherepnev G., Volk H.D., Volkmer-Engert R., et al. Analysis of antigen-specific T-cell responses with synthetic peptides-what kind of peptide for which purpose?. Hum. Immunol. 2004, 65(5):523-536.
33. Maecker H.T., Dunn H.S., Suni M.A., Khatamzas E., Pitcher C.J., Bunde T., et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods 2001, 255(1-2):27-40.
34. Draenert R., Altfeld M., Brander C., Basgoz N., Corcoran C., Wurcel A.G., et al. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J. Immunol. Methods 2003, 275(1-2):19-29.
35. Rammensee H.G., Falk K., Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 1993, 11:213-244.
36. Babel N., Volk H.D., Reinke P. BK polyomavirus infection and nephropathy: the virus-immune system interplay. Nat. Rev. Nephrol. 2011, 7(7):399-406.
37. Trydzenskaya H., Sattler A., Muller K., Schachtner T., Dang-Heine C., Friedrich P., et al. Novel approach for improved assessment of phenotypic and functional characteristics of BKV-specific T-cell immunity. Transplantation 2011, 92(11):1269-1277.
38. Mueller K., Schachtner T., Sattler A., Meier S., Friedrich P., Trydzenskaya H., et al. BK-VP3 as a new target of cellular immunity in BK virus infection. Transplantation 2011, 91(1):100-107.
39. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 2005, 202(5):673-685.
40. Lozza L., Lilleri D., Percivalle E., Fornara C., Comolli G., Revello M.G., et al. Simultaneous quantification of human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells. Eur. J. Immunol. 2005, 35(6):1795-1804.
41. Gerna G., Lilleri D., Furione M., Baldanti F. Management of human cytomegalovirus infection in transplantation: validation of virologic cut-offs for preemptive therapy and immunological cut-offs for protection. New Microbiol. 2011, 34(3):229-254.
42. van Besouw N.M., Verjans G.M., Zuijderwijk J.M., Litjens N.H., Osterhaus A.D., Weimar W. Systemic varicella zoster virus reactive effector memory T-cells impaired in the elderly and in kidney transplant recipients. J. Med. Virol. 2012, 84(12):2018-2025.
43. Lilleri D., Zelini P., Fornara C., Comolli G., Gerna G. Inconsistent responses of cytomegalovirus-specific T cells to pp65 and IE-1 versus infected dendritic cells in organ transplant recipients. Am. J. Transplant. 2007, 7(8):1997-2005.
44. Smith J.G., Joseph H.R., Green T., Field J.A., Wooters M., Kaufhold R.M., et al. Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin. Vaccine Immunol. 2007, 14(5):527-537.
45. Perfetto S.P., Chattopadhyay P.K., Lamoreaux L., Nguyen R., Ambrozak D., Koup R.A., et al. Amine-reactive dyes for dead discrimination in fixed samples. Curr. Protoc. Cytom. 2010, 34. Chapter 9: Unit 9.
46. Letsch A., Scheibenbogen C. Quantification and characterization of specific T-cells by antigen-specific cytokine production using ELISPOT assay or intracellular cytokine staining. Methods 2003, 31(2):143-149.
47. Currier J.R., Kuta E.G., Turk E., Earhart L.B., Loomis-Price L., Janetzki S., et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 2002, 260(1-2):157-172.
48. Mahnke Y.D., Roederer M. Optimizing a multicolor immunophenotyping assay. Clin. Lab. Med. 2007, 27(3):469-485. v.
49. Maecker H.T., McCoy J.P., Nussenblatt R. Standardizing immunophenotyping for the human immunology project. Nat. Rev. Immunol. 2012, 12(3):191-200.
50. Maecker H.T., McCoy J.P., Amos M., Elliott J., Gaigalas A., Wang L., et al. A model for harmonizing flow cytometry in clinical trials. Nat. Immunol. 2010, 11(11):975-978.
51. Jung T., Schauer U., Heusser C., Neumann C., Rieger C. Detection of intracellular cytokines by flow cytometry. J. Immunol. Methods 1993, 159(1-2):197-207.
52. Klausner R.D., Donaldson J.G., Lippincott-Schwartz J., Brefeldin A. Insights into the control of membrane traffic and organelle structure. J. Cell. Biol. 1992, 116(5):1071-1080.
53. Harari A., Cellerai C., Bellutti Enders F., Kostler J., Codarri L., Tapia G., et al. Skewed association of polyfunctional antigen-specific CDT cell populations with HLA-B genotype. Proc. Natl. Acad. Sci. U.S.A 2007, 104(41):16233-16238.
54. Pantaleo G., Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat. Rev. Immunol. 2006, 6(5):417-423.
55. Precopio M.L., Betts M.R., Parrino J., Price D.A., Gostick E., Ambrozak D.R., et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J. Exp. Med. 2007, 204(6):1405-1416.
56. Lalvani A., Brookes R., Hambleton S., Britton W.J., Hill A.V., McMichael A.J. Rapid effector function in CD8+ memory T cells. J. Exp. Med. 1997, 186(6):859-865.
57. Abate D., Saldan A., Forner G., Tinto D., Bianchin A., Palù G. Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants. J. Virol. Methods 2014, 196:157-162.
58. Calarota S.A., Chiesa A., Scaramuzzi L., Adzasehoun K.M., Comolli G., Mangione F., et al. Normalizing ELISPOT responses to T-cell counts: a novel approach for quantification of HCMV-specific CD4(+) and CD8(+) T-cell responses in kidney transplant recipients. J. Clin. Virol. 2014, 61(1):65-73.
59. Asai T., Storkus W.J., Whiteside T.L. Evaluation of the modified ELISPOT assay for gamma interferon production in patients receiving antitumor vaccines. Clin. Diagn. Lab. Immunol. 2000, 7(2):145-154.
60. Schmittel A., Keilholz U., Scheibenbogen C. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J. Immunol. Methods 1997, 210(2):167-174.
61. Bestard O., Crespo E., Stein M., Lucia M., Roelen D.L., de Vaal Y.J., et al. Cross-validation of IFN-gamma Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. Am J Transplant. 2013, 13(7):1880-1890.
62. Ahlborg N., Axelsson B. Dual- and triple-color fluorospot. Methods Mol. Biol. 2012, 792:77-85.
63. Boulet S., Ndongala M.L., Peretz Y., Boisvert M.P., Boulassel M.R., Tremblay C., et al. A dual color ELISPOT method for the simultaneous detection of IL-2 and IFN-gamma HIV-specific immune responses. J. Immunol. Methods 2007, 320(1-2):18-29.
64. Rebhahn J.A., Bishop C., Divekar A.A., Jiminez-Garcia K., Kobie J.J., Lee F.E., et al. Automated analysis of two- and three-color fluorescent Elispot (Fluorospot) assays for cytokine secretion. Comput. Methods Programs Biomed. 2008, 92(1):54-65.
65. Karulin A.Y., Hesse M.D., Tary-Lehmann M., Lehmann P.V. Single-cytokine-producing CD4 memory cells predominate in type 1 and type 2 immunity. J. Immunol. 2000, 164(4):1862-1872.
66. Okamoto Y., Abe T., Niwa T., Mizuhashi S., Nishida M. Development of a dual color enzyme-linked immunospot assay for simultaneous detection of murine T helper type 1- and T helper type 2-cells. Immunopharmacology 1998, 39(2):107-116.
67. Quast S., Zhang W., Shive C., Kovalovski D., Ott P.A., Herzog B.A., et al. IL-2 absorption affects IFN-gamma and IL-5, but not IL-4 producing memory T cells in double color cytokine ELISPOT assays. Cell. Immunol. 2005, 237(1):28-36.
68. Calarota S.A., Baldanti F. Enumeration and characterization of human memory T cells by enzyme-linked immunospot assays. Clin. Dev. Immunol. 2013, 2013:637649.
69. Engstrand M., Tournay C., Peyrat M.A., Eriksson B.M., Wadstrom J., Wirgart B.Z., et al. Characterization of CMVpp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants. Transplantation 2000, 69(11):2243-2250.
70. Batard P., Peterson D.A., Devevre E., Guillaume P., Cerottini J.C., Rimoldi D., et al. Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells. J. Immunol. Methods 2006, 310(1-2):136-148.
71. Scholler J., Singh M., Bergmeier L., Brunstedt K., Wang Y., Whittall T., et al. A recombinant human HLA-class I antigen linked to dextran elicits innate and adaptive immune responses. J. Immunol. Methods 2010, 360(1-2):1-9.
72. Knabel M., Franz T.J., Schiemann M., Wulf A., Villmow B., Schmidt B., et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat. Med. 2002, 8(6):631-637.
73. Tischer S., Kaireit T., Figueiredo C., Hiller O., Maecker-Kolhoff B., Geyeregger R., et al. Establishment of the reversible peptide-major histocompatibility complex (pMHC) class I Histamer technology: tool for visualization and selection of functionally active antigen-specific CD8(+) T lymphocytes. Int. Immunol. 2012, 24(9):561-572.
74. Tischer S., Dieks D., Sukdolak C., Bunse C., Figueiredo C., Immenschuh S., et al. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches. J. Immunol. Methods 2014, 408:101-113.
75. ®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert Rev. Mol. Diagn. 2011, 11(1):17-25.
76. Abate D., Saldan A., Mengoli C., Fiscon M., Silvestre C., Fallico L., et al. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. J. Clin. Microbiol. 2013, 51(8):2501-2507.
77. Egli A., Humar A., Kumar D. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin. Infect. Dis. 2012, 55(12):1678-1689.
78. Melendez D., Razonable R.R. Immune-based monitoring for cytomegalovirus infection in solid organ transplantation: is it ready for clinical primetime?. Expert Rev. Clin. Immunol. 2014, 10(9):1213-1227.
79. Manuel O. Clinical experience with immune monitoring for cytomegalovirus in solid-organ transplant recipients. Curr. Infect. Dis. Rep. 2013, 15:491-496.
80. Lúcia M., Crespo E., Cruzado J.M., Grinyó J.M., Bestard O. Human CMV-specific T-cell responses in kidney transplantation; toward changing current risk-stratification paradigm. Transpl. Int. 2014, 27(7):643-656.
81. Fernández-Ruiz M., Kumar D., Humar A. Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation. Clin. Transl. Immunol. 2014, 3(2):e12.
82. Bestard O., Lucia M., Crespo E., Van Liempt B., Palacio D., Melilli E., et al. Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation. Am. J. Transplant. 2013, 13(7):1793-1805.
83. Cantisán S., Lara R., Montejo M., Redel J., Rodríguez-Benot A., Gutiérrez-Aroca J., et al. Pretransplant interferon-(secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am. J. Transplant. 2013, 13(3):738-745.
84. Bunde T., Kirchner A., Hoffmeister B., Habedank D., Hetzer R., Cherepnev G., et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J. Exp. Med. 2005, 201(7):1031-1036.
85. López-Oliva M.O., Martinez V., Buitrago A., Jiménez C., Rivas B., Escuin F., et al. Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant. Transplantation 2014, 97(8):839-845.
86. Shabir S., Kaul B., Pachnio A., Banham G.D., Smith H., Chand S., et al. Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation. J. Am. Soc. Nephrol. 2013, 24(10):1698-1708.
87. Abate D., Fiscon M., Saldan A., Cofano S., Mengoli C., Sgarabotto D., et al. Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection. J. Clin. Microbiol. 2012, 50(6):1974-1980.
88. Costa C., Balloco C., Sidoti F., Mantovani S., Rittà M., Piceghello A., et al. Evaluation of CMV-specific cellular immune response by EliSPOT assay in kidney transplant patients. J. Clin. Virol. 2014, 61(4):523-528.
89. Kumar D., Chernenko S., Moussa G., Cobos I., Manuel O., Preiksaitis J., et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am. J. Transplant. 2009, 9(5):1214-1222.
90. Manuel O., Husain S., Kumar D., Zayas C., Mawhorter S., Levi M.E., et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin. Infect. Dis. 2013, 56(6):817-824.
91. Lisboa L.F., Kumar D., Wilson L.E., Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012, 93(2):195-200.
92. Weseslindtner L., Kerschner H., Steinacher D., Nachbagauer R., Kundi M., Jaksch P., et al. Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients. Am. J. Transplant. 2012, 12(8):2172-2180.
93. Weseslindtner L., Kerschner H., Steinacher D., Kundi M., Jaksch P., Simon B., et al. Association of human cytomegalovirus DNAaemia and specific granzyme B responses in lung transplant recipients. Clin. Exp. Immunol. 2013, 173(3):438-443.
94. Egli A., Binet I., Binggeli S., Jäger C., Dumoulin A., Schaub S., et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J. Transl. Med. 2008, 6:29.
95. Sund F., Lidehäll A.K., Claesson K., Foss A., Tötterman T.H., Korsgren O., et al. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study. Clin. Transplant. 2010, 24(3):401-409.
96. Eid A.J., Brown R.A., Arthurs S.K., Lahr B.D., Eckel-Passow J.E., Larson T.S., et al. A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection. Transpl. Int. 2010, 23(5):506-513.
97. Gerna G., Lilleri D., Fornara C., Comolli G., Lozza L., Campana C., et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am. J. Transplant. 2006, 6(10):2356-2364.
98. Gerna G., Lilleri D., Chiesa A., Zelini P., Furione M., Comolli G., et al. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am. J. Transplant. 2011, 11(11):2463-2471.
99. Rickinson A.B., Long H.M., Palendira U., Münz C., Hislop A.D. Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory. Trends Immunol. 2014, 35(4):159-169.
100. San-Juan R., Comoli P., Caillard S., Moulin B., Hirsch H.H., Meylan P. ESCMID study group of infection in compromised hosts. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clin. Microbiol. Infect. 2014, 20(Suppl 7):109-118.
101. Macedo C., Donnenberg A., Popescu I., Reyes J., Abu-Elmagd K., Shapiro R., et al. EBV-specific memory CD8+ T cell phenotype and function in stable solid organ transplant patients. Transpl. Immunol. 2005, 14(2):109-116.
102. Calarota S.A., Chiesa A., Zelini P., Comolli G., Minoli L., Baldanti F. Detection of Epstein-Barr virus-specific memory CD4+ T cells using a peptide-based cultured enzyme-linked immunospot assay. Immunology 2013, 139(4):533-544.
103. Rittà M., Costa C., Sinesi F., Sidoti F., Di Nauta A., Mantovani S., et al. Evaluation of Epstein-Barr virus-specific immunologic response in solid organ transplant recipients with an enzyme-linked ImmunoSpot assay. Transplant. Proc. 2013, 45(7):2754-2757.
104. Yang J., Lemas V.M., Flinn I.W., Krone C., Ambinder R.F. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. Blood 2000, 95(1):241-248.
105. Guppy A.E., Rawlings E., Madrigal J.A., Amlot P.L., Barber L.D. A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease. Transplantation 2007, 84(11):1534-1539.
106. Sebelin-Wulf K., Nguyen T.D., Oertel S., Papp-Vary M., Trappe R.U., Schulzki A., et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl. Immunol. 2007, 17(3):203-210.
107. Mees S.T., Kebschull L., Mardin W.A., Senninger N., Suwelack B., Wolters H., et al. Detection of different virus-specific CD8+ T Cells after kidney transplantation. Surg. Infect. (Larchmt) 2014, 15(3):274-282.
108. Hislop A.D., Taylor G.S., Sauce D., Rickinson A.B. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 2007, 25:587-617.
109. Merlo A., Turrini R., Dolcetti R., Zanovello P., Rosato A. Immunotherapy for EBV-associated malignancies. Int. J. Hematol. 2011, 93(3):281-293.
110. Bollard C.M., Rooney C.M., Heslop H.E. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat. Rev. Clin. Oncol. 2012, 9(9):510-519.
111. Comoli P., Cioni M., Basso S., Gagliardone C., Potenza L., Verrina E., et al. Immunity to Polyomavirus BK. Infection: immune monitoring to regulate the balance between risk of BKV nephropathy and induction of alloimmunity. Clin. Dev. Immunol. 2013, 2013:256923.
112. Binggeli S., Egli A., Schaub S., Binet I., Mayr M., Steiger J., et al. Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am. J. Transplant. 2007, 7(5):1131-1139.
113. Prosser S.E., Orentas R.J., Jurgens L., Cohen E.P., Hariharan S. Recovery of BK virus large T-antigen-specific cellular immune response correlates with resolution of BK virus nephritis. Transplantation 2008, 85(2):185-192.
114. Chakera A., Bennett S., Lawrence S., Morteau O., Mason P.D., O'Callaghan C.A., et al. Antigen-specific T. cell responses to BK polyomavirus antigens identify functional anti-viral immunity and may help to guide immunosuppression following renal transplantation. Clin. Exp. Immunol. 2011, 165(3):401-409.
115. Schachtner T., Müller K., Stein M., Diezemann C., Sefrin A., Babel N., et al. BK virus-specific immunity kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy. Am. J. Transplant. 2011, 11(11):2443-2452.
116. Costa C., Mantovani S., Piceghello A., Di Nauta A., Sinesi F., Sidoti F., et al. Evaluation of polyomavirus BK cellular immune response by an ELISpot assay and relation to viral replication in kidney transplant recipients. New Microbiol. 2014, 37(2):219-223.
117. Comoli P., Azzi A., Maccario R., Basso S., Botti G., Basile G., et al. Polyomavirus BK-specific immunity after kidney transplantation. Transplantation 2004, 78(8):1229-1232.
118. Trydzenskaya H., Sattler A., Müller K., Schachtner T., Dang-Heine C., Friedrich P., Nickel P., Hoerstrup J., Schindler R., Thiel A., Melzig M.F., Reinke P., Babel N. Novel approach for improved assessment of phenotypic and functional characteristics of BKV-specific T-cell immunity. Transplantation 2011, 92(11):1269-1277.
119. Nebbia G., Mattes F.M., Smith C., Hainsworth E., Kopycinski J., Burroughs A., et al. Polyfunctional cytomegalovirus-specific CD4+ and pp65CD8+ T cells protect against high-level replication after liver transplantation. Am. J. Transplant. 2008, 8(12):2590-2599.
120. Pipeling M.R., John E.R., Orens J.B., Lechtzin N., McDyer J.F. Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients. J. Infect. Dis. 2011, 204(11):1663-1671.
121. Sester M., Sester U., Gartner B., Heine G., Girndt M., Mueller-Lantzsch N., et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001, 71(9):1287-1294.
122. Zhou W., Longmate J., Lacey S.F., Palmer J.M., Gallez-Hawkins G., Thao L., et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 2009, 113(25):6465-6476.
123. Crough T., Fazou C., Weiss J., Campbell S., Davenport M.P., Bell S.C., et al. Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8(+) T-cell response. J. Virol. 2007, 81(20):11538-11542.
124. Benmarzouk-Hidalgo O.J., Cisneros J.M., Cordero E., Martin-Pena A., Sanchez B., Martin-Gandul C., et al. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation 2011, 91(8):927-933.
125. Gamadia L.E., Remmerswaal E.B., Weel J.F., Bemelman F., van Lier R.A., Ten Berge I.J. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 2003, 101(7):2686-2692.
126. Abate D., Saldan A., Fiscon M., Cofano S., Paciolla A., Furian L., et al. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J. Infect. Dis. 2010, 202(4):585-594.
127. Mattes F.M., Vargas A., Kopycinski J., Hainsworth E.G., Sweny P., Nebbia G., et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am. J. Transplant. 2008, 8(5):990-999.
128. Nickel P., Bold G., Presber F., Biti D., Babel N., Kreutzer S., et al. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Transpl. Immunol. 2009, 20(4):238-242.
129. Chen F.E., Aubert G., Travers P., Dodi I.A., Madrigal J.A. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy. Cytotherapy 2002, 4(1):41-48.
130. Giest S., Grace S., Senegaglia A.C., Pasquini R., Gonzalo-Daganzo R.M., Fernandez M.N., et al. Cytomegalovirus-specific CD8(+) T cells targeting different HLA/peptide combinations correlate with protection but at different threshold frequencies. Br. J. Haematol. 2010, 148(2):311-322.
131. Tario J.D., Chen G.L., Hahn T.E., Pan D., Furlage R.L., Zhang Y., et al. Dextramer reagents are effective tools for quantifying CMV antigen-specific T cells from peripheral blood samples. Cytometry B. Clin. Cytom. 2015, 88(1):6-20.
132. Lochmanova A., Lochman I., Tomaskova H., Marsalkova P., Raszka J., Mrazek J., et al. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation. Transplant. Proc. 2010, 42(9):3574-3577.
133. Westall G.P., Mifsud N.A., Kotsimbos T., Linking C.M.V. serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am. J. Transplant. 2008, 8(8):1749-1754.
134. Chen Y., Trofe J., Gordon J., Autissier P., Woodle E.S., Koralnik I.J. BKV and JCV large T antigen-specific CD8+ T cell response in HLA A 0201+ kidney transplant recipients with polyomavirus nephropathy and patients with progressive multifocal leukoencephalopathy. J. Clin. Virol. 2008, 42(2):198-202.
135. Chen Y., Trofe J., Gordon J., Du Pasquier R.A., Roy-Chaudhury P., Kuroda M.J., et al. Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J. Virol. 2006, 80(7):3495-3505.